Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, Hofer F, Barouni RM, Musiu C, Caligola S, Pinton L, Torroni L, Polati E, Donadello K, Friso S, Pizzolo F, Iezzi M, Facciotti F, Pelicci PG, Righetti D, Bazzoni P, Rampudda M, Comel A, Mosaner W, Lunardi C, Olivieri O.
Bronte V, et al. Among authors: donadello k.
J Clin Invest. 2020 Dec 1;130(12):6409-6416. doi: 10.1172/JCI141772.
J Clin Invest. 2020.
PMID: 32809969
Free PMC article.
Clinical Trial.